Transparency in ovarian cancer clinical trial results : ClinicalTrials.gov versus PubMed, Embase and Google scholar by A. Roberto et al.
RESEARCH Open Access
Transparency in ovarian cancer clinical trial
results: ClinicalTrials.gov versus PubMed,
Embase and Google scholar
Anna Roberto*, Silvia Radrezza and Paola Mosconi
Abstract
Background: In recent years the question of the lack of transparency in clinical research has been debated by clinicians,
researchers, citizens and their representatives, authors and publishers. This is particularly important for infrequent cancers
such as ovarian cancer, where treatment still gives disappointing results in the majority of cases. Our aim was to assess the
availability to the public of results in ClinicalTrials.gov, and the frequency of non-publication of results in ClinicalTrials.gov
and in PubMed, Embase and Google Scholar. We collected all trials on ovarian cancer identified as “completed status” in
the ClinicalTrials.gov registry on 17 January 2017. We checked the availability of the results in ClinicalTrials.gov and
systematically identified published manuscripts on results.
Results: Out of 2725 trials on ovarian cancer identified, 752 were classified as “completed status”. In those closed between
2008 and 2015, excluding phase I, the frequency of results in ClinicalTrials.gov was 35%. Of the 752 completed studies the
frequency of published results in PubMed, Embase or Google Scholar ranged from 57.9% to 69.7% in the last years.
Conclusions: These findings show a lack of transparency and credibility of research. Citizens or patients’ representatives,
with the medical community, should continuously support initiatives to improve the publication and dissemination of
clinical study results.
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Background
The lack of transparency of clinical research results has
long been on the agenda of clinicians [1], researchers,
citizens and their representatives [2, 3], authors and
publishers [4, 5]. The AllTrials petition on the transpar-
ency of clinical data is attracting widespread interest [4],
and the “Restoring Invisible and Abandoned Trials” ini-
tiative is making public the confidential results about
missing and abandoned trials [6]. “Better reporting of
better research” is the motto shared by citizens and pa-
tients [7], and also underlined recently by members of
the European Parliament [8].
To facilitate access to clinical trial information, in 1997
the database ClinicalTrials.gov was developed through the
US Food and Drug Administration Modernization Act.
This is the world’s largest clinical trial registry, public and
accessible to citizens [9, 10]. In 2005, the “International
Committee of Medical Journal Editors” implemented a
policy requiring prospective registration of clinical trials
for publication in its member journals [11]. In 2007, the
US Food and Drug Administration Amendments Act
[FDAAA] required trial results to be reported in Clinical-
Trials.gov, within one year from completion and regard-
less of whether the results had been published [12].
Finally, in 2008, the ClinicalTrials.gov registry expanded
its database to include a section reporting basic summary
results [13, 14]. Nevertheless, compliance with the report-
ing of results continued to be lacking, probably because
some statutory requirements were ambiguous.
In September 2016, the US Department of Health and
Human Services published a final rule to increase the ac-
countability of all clinical research stakeholders by ex-
pansion of minimum data sets about legal requirements
under FDAAA for trial registration and submission of
results. The final rule became effective on 18 January
2017 through those responsible had until 18 April 2017
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to become familiar and compliant with it. At the same
time, the Nation Institute of Health issued a comple-
mentary final policy [15].
Ovarian cancer can be considered a rare disease in
comparison with other major oncological killers, even if
it is the fifth most common cancer among women.
About 65,000 women are diagnosed every year in Eur-
ope, and 42,000 die each year [16]. No early diagnosis is
available and the results of treatment are still poor for
the majority of cases. It is therefore essential that any re-
sults of clinical research, positive or negative, be pub-
lished to permit broad discussion of the different
strategies for care.
The aims of this study were to evaluate the availability
of basic summary results of registered clinical trials in
ovarian cancer in ClinicalTrials.gov, and the frequency
of non-publication of results in ClinicalTrials.gov and in
PubMed, Embase or Google Scholar.
Methods
From January to September 2017, we examined all com-
pleted clinical trials on ovarian cancer registered in Clin-
icalTrials.gov in terms of the frequency of results
published in PubMed, Embase and Google Scholar.
ClinicalTrials.gov database
Using the “advanced search” function of ClinicalTrials.
gov we searched for trials on ovarian cancer. Only those
listed as “completed status”, indicating that the trial was
ended normally, were included. All these reports were
downloaded as an XML data set (12 January 2017). For
each one we considered the following: starting date,
study design (observational or interventional), type of
study (diagnostic, therapeutic, supportive care, preven-
tion and screening, health services research), country,
multicentric (yes or no), funding source (profit or not-
for-profit), number of primary outcomes, nature of the
primary outcomes, enrolment of participants, and sam-
ple size. These variables collected in the ClinicalTrials.
gov registration database are described in the Data
Element Definitions document issued by the National
Library of Medicine [17]. Trials not on ovarian cancer or
closed after 2015 were excluded.
PubMed database
For each trial in this analysis, we used the link within
ClinicalTrials.gov in order to identify the published art-
icle. If this was not possible, we systematically searched
for the publication in PubMed, Embase and Google
Scholar through the following keywords: trial unique
registration number, trial title, principal investigator’s
name, and treatment. We considered a trial as “pub-
lished” when a peer-reviewed publication was found, ei-
ther online or in print, including any data. We then
confirmed the publication identity by comparing inclu-
sion and exclusion criteria, trial arms, type of outcomes,
treatment and comparator, sample size and primary in-
vestigator names in the registration record. For each art-
icle the year of publication and the journal, the primary
and secondary outcomes, sample size and impact factor
(IF) were collected. We examined the correspondence
between the journal publication and trial registered, as
reported in ClinicalTrials.gov. The outcome correspond-
ence analysis was conducted by IF less or more than 10
and by profit or not-for-profit. Finally, we calculated the
mean time to publication of the results.
Basic summary results section in ClinicalTrials.gov
As the section reporting summary results has been avail-
able in ClinicalTrials.gov since 2008, we verified whether
it had been completed on a subsample of the trials that
ended between 2008 and 2015. Phase I trials were not
considered as their results are not required to be pub-
lished in ClinicalTrials.gov [12]. The variables collected
in the ClinicalTrials.gov registration database are de-
scribed in the Basic Results Data Element Definitions
document issued by the National Library of Medicine
[18]. Generally this section reports descriptive statistics
on the characteristics of patients enrolled, and the re-
sults for the primary and secondary outcomes.
Statistical analyses
For continuous variables, means, medians and standard
deviations were obtained. For categorical variables, pro-
portions were obtained. All descriptive analyses were
done using SAS, version 9.4.
Results
As described in the flow-chart (Fig. 1), out of 2725 stud-
ies retrieved by the search through ClinicalTrials.gov we
identified 1195 with “completed status”. The final set, re-
lated to ovarian cancer and closed in 2015, comprised
752 completed studies. To examine this database we
considered the following groups: 254 completed before
2008; 122 completed Phase I trials closed between 2008
and 2015; 376 other completed studies closed between
2008 and 2015.
Table 1 illustrates the main features of completed
studies. Most were Phase II, multicentre trials, con-
ducted in America, for treatment purposes. Safety and
efficacy were the most common endpoints, and major
were not-for-profit. There was a large amount of missing
data for the endpoint classification and center. The
mean duration was 4.5 years.
The mean time to journal publication was 2.5 years
(SD 1.8, range 1–11) only for reports published after the
end of the trials (data not shown).
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Table 2 compares the primary and secondary outcomes
reported in published articles and in the trials registered
in ClinicalTrials.gov. The frequency of publication of re-
sults in the ClinicalTrials.gov section among “other stud-
ies” completed between 2008 and 2015 is nearly 35%. For
the primary outcome, 51.8% of all trials corresponded, but
37.8% were not declared in ClinicalTrials.gov. The figures
for secondary outcome were 39.3% of all trials. In this
case, the percentage of secondary outcomes not declared
in ClinicalTrials.gov reached 44.5%.
A total of 94 reports of trials completed between 2008
and 2015 did not report results either in ClinicalTrials.
gov or in a publication available in PubMed, Embase or
Google Scholar (Table 3).
Comparison of the information reported in the pub-
lished articles and in the results’ section of Clinical-
Trials.gov (Table 4) shows several discrepancies between
what was declared and what was actually published. One
hundred and five different journals were found, with an
average IF of 10.3 (range 1.5–72.4). For 10 of them no IF
was declared. On primary outcomes the correspondence
between journal publication and ClinicalTrials.gov trials
is similar in both groups (Table 4). Outcome corres-
pondence was less common in the journals with IF≥10.
In the high IF journals it was more frequent not to de-
clare primary outcome in ClinicalTrials.gov.
The correspondence for secondary outcomes was simi-
lar in both groups. These results suggest that the quality
of outcome reported was not significantly influenced by
the IF.
We retrieved a total of 463 not-for-profit trials and
289 for profit. Only studies published between 2008 and
2015 were analyzed. The main features such as trial
phase, center, purpose, etc., were described and com-
pared (Table 5).
As for the IF, we verified the outcome correspondence
between journals and ClinicalTrials.gov not-for-profit
and profit trials separately. The correspondence of
Fig. 1 Flow-chart describing the selection of ovarian cancer trials and the availability of results
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Table 1 Main features of the trials reported in ClinicalTrials.gov
ClinicalTrials.gov studies All (752) < 2008 (254) 2008–2015 (498)
N % N % N %
Study phase
0 3 0.4 – – 3 0.6
I 186 24.7 67 26.4 119 23.9
I-II 54 7.2 21 8.3 33 6.6
II 313 41.6 114 44.9 199 40.0
II-III 6 0.8 2 0.8 4 0.8
III 67 8.9 21 8.3 46 9.2
IV 7 0.9 2 0.8 5 1.0
Observational 71 9.4 18 7.1 53 10.6
Missing 45 6.0 9 3.5 36 7.2
Center
Multicenter 393 52.3 106 41.7 287 57.6
Single-center 208 27.7 76 29.9 132 26.5
Missing 151 20.1 72 28.4 79 15.9
Countrya
America 489 65.0 195 76.8 294 59.0
Europe 114 15.2 25 9.8 89 17.9
International 99 13.1 17 6.7 82 16.5
Asia 21 2.8 4 1.6 17 3.4
Oceania 3 0.4 – – 3 0.6
Study purposea
Treatment 612 81.4 213 83.9 399 80.1
Prevention and screening 20 2.7 6 2.4 14 2.8
Diagnostic 15 2.0 2 0.8 13 2.6
Supportive care 29 3.9 12 4.7 17 3.4
Health services research 5 0.7 1 0.4 4 0.8
Other 34 4.5 4 1.6 30 6.0
Missing 37 5.0 16 6.3 21 4.2
Endpoint classification
Efficacy 168 22.3 67 26.4 101 20.3
Safety 80 10.6 27 10.6 53 10.6
Safety and efficacy 256 34.0 68 26.8 188 37.8
Other 106 14.1 18 7.1 88 17.7
Missing 142 19.0 74 29.1 68 13.7
Sponsor
Not-for-profit 463 61.6 189 74.4 274 55.0
Profit 289 38.4 65 25.6 224 45.0
Study duration (years)
Mean (SD) 4.48 (2.8) 4.12 (2.9) 4.64 (2.7)
Range 1–24 1–24 1–21
Number of subjects
< 50 382 51.6 142 37.2 240 62.8
≥ 50 359 48.5 105 29.3 254 70.8
aSome discrepancies in the total are due to missing data; less than 5% of data are missing
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primary outcomes was similar in both samples with a
total correspondence between two sources of 76.2%.
For the secondary outcome, however, for profit trials
corresponded more closely, with 64.2% vs. 43.2% re-
spectively (Table 6).
Discussion
Several papers indicate a worrisome percentage of clin-
ical trials whose results are not available for clinicians,
researchers and citizens or patients [2, 19–23]. To our
knowledge this topic is still less deepened in ovarian
cancer field. Some publications are consistent with our
results showing there is still a general need for transpar-
ency in publication of findings. Guo and colleagues re-
ported that 69% of a sample of 35 clinical trials on
endometriosis were unpublished [19]. As regards the
links between ClinicalTrials.gov and PubMed, Huser and
Cimino [20] reported that the majority of 8907 trials
(72%] had no structured trial-article link available, and
55% of so-called “silent” trials had no linked results art-
icle or even basic summary results. Such under-
reporting can contribute to biased evidence, with serious
consequences for clinical practice, research and, in the
end, for patients [21, 24]. Pranic and Marusic [25] report
a similar result about 81 eligible trials found in Clinical-
Trials.gov between 2009 and 2012. In this sample, the
secondary outcomes were left out for 17% at the initial
registration and for 19.7% at the last.
Basing on our analysis aimed on ovarian cancer, very
high percentages of completed ovarian cancer clinical
trials - about a quarter - do not see the light either in
the specific results section of ClinicalTrials.gov or in
medical journals.
Also important are the inconsistencies between the tri-
als registered and the published primary and secondary
outcomes. These inconsistencies are also present in the
ClinicalTrials.gov results section. From the viewpoint of
citizens or patients a complete results section in a public
registry such as ClinicalTrials.gov should offer an easy
way to find complete information about all registered
clinical trials. On the single level, this could facilitate
decision-making on new treatments or even new clinical
trials [1, 26]. At the community level, for example for
patients’ associations, the results could help in identify-
ing uncertainties or answering questions about the ef-
fects of treatments and discussing research priorities.
From the researchers’ point of view the lack of access to
all trial results contributes to publication bias [2], to
misuse of systematic reviews, meta-analyses and clinical
guidelines and, finally, reduces the possibility of design-
ing innovative research. Even more important, from the
clinicians’ point of view this lack of information on re-
sults can lead to an unfair doctor-patient relationship,
where advice on care and treatment is not in line with
the latest knowledge.
Researchers and sponsors have a great responsibility to
report results and data related to their clinical research
Table 2 Trials published and correspondence between outcomes in the publication and ClinicalTrials.gov
N % N % N % N %
Results Reported in All (752) < 2008 (254) 2008-2015a (498)
Phase I (122) Other studies types (376)
ClinicalTrials.gov NA NA NA 130 34.6
Journal publication 483 64.2 147 57.9 74 60.7 262 69.7
Outcome correspondence All (483) < 2008 (147) Phase I (74) Other studies types (262)
Primary Outcome
Corresponded 249 51.8 40 27.0 37 50.7 172 66.2
Not corresponded 50 10.4 13 8.8 7 9.6 30 11.5
Not declared in ClinicalTrials.gov 182 37.8 95 64.2 29 39.7 58 22.3
Secondary Outcome
Corresponded 157 39.3 24 19.1 27 41.5 106 50.7
Not corresponded 65 16.2 14 11.1 7 10.8 44 21.1
Not declared in ClinicalTrials.gov 178 44.5 88 69.8 31 47.7 59 28.2
NA, Not applicable
aSee the number reported in the highlighted boxes in Fig. 1
Table 3 Results in ClinicalTrials.gov and journal publication for
trials ended between 2008 and 2015 (N 376)
ClinicalTrials.gov
Journal publication Yes - N (%) No - N (%)
Yes - N (%) 110 (29.3) 152 (40.4)
No - N (%) 20 (5.3) 94 (25.0)
Total 130 (34.6) 246 (65.4)
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fully, as recently underlined by the new European Medi-
cines Agency regulation on trial publication [27].
Nevertheless, it is not easy to investigate the cause of
this marked lack of transparency as many factors can con-
tribute, such as career, market and sponsors, or conflict of
interest. Probably until a few years ago some researchers
did not even consider the lack of transparency an import-
ant issue that could help improve the quality of research
and reduce waste. Moreover there was no public opinion
movement, such as the AllTrials campaign [4], which
could lead to greater transparency. And yet ensuring
greater transparency would only need a little effort on the
part of researchers, who should be anxious to register
publicly their trials and make the results public as re-
quired by FDAAA [13]. It also defined criteria and a
checklist of mandatory registration data or documents, to
register and then to publish results [28]. To guarantee a
standard method for reporting results, there are also inter-
national guidelines such as CONSORT 2010 (Consoli-
dated Standards of Reporting Results) [29] and ICH E3
(International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Hu-
man Use) [30].
In addition, to improve the clarity and boost the
spread of information, data sharing is encouraged and is
considered a new “gold standard” by all scientific stake-
holders; several initiatives or projects are planned to in-
crease it. Researchers can, through specific platforms,
have access to anonymized patients’ data from several
clinical trials, and other documentation to conduct fur-
ther research [31]. As regards the homogenization of
procedures to plan and conduct a clinical trial, the Euro-
pean Community has drawn up the New Regulation
536/2014. Its first aim is to improve the transparency of
the data collected by all European trials and to make
them public. The Regulation also defines the standards
to assure the safety and quality of research, fostering col-
laboration among Member States [32].
Recently, the editors of peer-reviewed journals have
become more willing to publish negative trials results
and to check the consistency of information to be pub-
lished with that reported in registers such as Clinical-
Trials.gov [25].
Finally, citizens, patients and their associations can all
do something to obtain greater transparency in research:
for example, associations and public funders can decide
to finance only trials which expressly state they will ad-
here to the rules of transparency.
As ovarian cancer is so infrequent, disclosure of study
results is an ethical duty from the moment patients are
enrolled, and this should be fully stated in the informed
consent form. The latest version of the Declaration of
Helsinki exhorts researchers, authors, sponsors, editors
and publishers to report and disseminate positive or
negative results of clinical research [33]. What patient
would be willing to participate in a clinical trial if the
data collected will not be useful to anyone - neither the
scientific community nor other patients? Associations of
citizens or patients could be also more forceful in de-
manding more transparency in reporting results, and
offer their support only to researchers or multicenter
groups that guarantee full disclosure.
The sample of trials that did not report the results ei-
ther in a journal or in the results section in Clinical-
Trials.gov amounted to about 30% of those on recurrent
platinum-resistant ovarian cancer, and about 30% with
advanced ovarian cancer. Only a few trials involved
newly-diagnosed women or those in the first line of
treatment. Nearly half the trials were Phase II, and one-
tenth were observational.
In our sample not only was the results section often
missing, but single items required during the registration
in ClinicalTrials.gov were often lacking too: for example,
the nature of the study, or the endpoint classification.
On the other hand, it is worth noting the limited
amount of data missing among all the items required
Table 4 Correspondence between outcomes in publications and ClinicalTrials.gov, based on Impact Factor
Outcome correspondence based on Impact Factor Impact factor≥ 10 (18a) Impact factor < 10 (75a) Total (93)
N % N % N %
Primary Outcome
Corresponded 19 73.1 62 79.5 81 77.9
Not corresponded 2 7.7 11 14.1 13 12.5
Not declared in ClinicalTrials.gov 5 19.2 5 6.4 10 9.6
Secondary Outcome
Corresponded 11 57.9 36 54.6 47 55.3
Not corresponded 5 26.3 16 24.2 21 24.7
Not declared in ClinicalTrials.gov 3 15.8 14 21.2 17 20.0
aNumber of journals with IF less than 10 or more according to each subgroup. The same journal could have published several articles
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now for registration in the clinical trials whose results
were reported both in ClinicalTrials.gov and in a journal.
This shows that a high level of data reporting is possible
with little extra effort.
The inconsistencies between the trial registered and
the published results on primary and secondary out-
comes are not to be overlooked; these inconsistencies
are also present in the ClinicalTrials.gov results section
but also in journals with IF of 10 or more. In fact, a
quality analysis based on the IF it does not show any ap-
preciable differences between the two groups. These re-
sults are in line with a previous cross-sectional analysis
[34] of 96 clinical trials. These trials were published in
2010–2011 in PubMed, in high-impact journals (IF≥10)
and the results were registered and reported in Clinical-
Trials.gov; nearly all had at least one discrepancy in the
cohort, intervention, primary endpoints or results re-
ported in the two sites. In addition, Smith et al. [35] re-
ported disparity for 79% of the registry-publication pairs
especially about primary outcomes.
Results that we retrieved were similar for the analysis
among not-for-profit and for-profit trials. This implies,
that efforts to improve the quality and transparency of
data published are still needed especially for secondary
outcomes.
At the end of a trial, the analysis should include publi-
cation of the results on the basis of the primary outcome
on which the trial was designed, and also the sample
size. Not disclosing the primary outcome, but only the
secondary one, can have a detrimental impact in the sci-
entific community, who do not receive the right infor-
mation, and on patients who participated in the not
properly designed trial. Moreover, future studies can be
damaged too as other researchers can may design new
trials on the basis of previous uncorrected results. Fi-
nally, it is unethical to ask a patient informed consent
for to take part in a trial with a defined endpoint, and
then not to make the result public.
Table 5 Main features of not-for-profit and profit trials ended
between 2008 and 2015
ClinicalTrials.gov studies Not-for-profit
2008–2015 (274)
Profit 2008–2015
(224)
N % N %
Study phase
0 3 16.5 – –
I 46 19.0 73 33.2
I-II 18 7.4 15 6.8
II 103 42.6 96 43.6
II-III – – 4 1.8
III 29 12.0 17 7.7
IV 3 1.2 2 0.9
Observational 40 16.5 13 5.9
Missing 32 4
Center
Multicenter 125 58.7 162 78.6
Single-center 88 41.3 44 21.4
Missing 61 18
Country
America 178 66.4 116 53.5
Europe 64 23.9 25 11.5
International 16 6.0 66 30.4
Asia 8 3.0 9 4.2
Oceania 2 0.8 1 0.5
Study purpose
Treatment 196 76.0 203 92.7
Prevention and
screening
10 3.9 4 1.8
Diagnostic 8 3.1 5 2.3
Supportive care 15 5.8 2 0.9
Health services research 3 1.2 1 0.5
Other 26 10.1 4 1.8
Missing 16
Endpoint classification
Efficacy 71 32.0 30 14.4
Safety 18 8.1 35 16.8
Safety and efficacy 78 35.1 110 52.9
Other 55 24.8 33 15.9
Missing 52 16
Study duration (years)
- Mean (SD)
5.27 (3.00) 3.74 (2.17)
Number of subjects
< 50 128 46.7 112 50.0
> =50 143 52.2 111 49.5
Table 6 Correspondence between outcomes in publications
and ClinicalTrials.gov among “not-for-profit” vs “profit” studies
Outcome correspondence Not-for-profit (52) Profit (58)
N % N %
Primary Outcomea
Corresponded 39 76.5 44 75.9
Not corresponded 7 13.7 7 12.1
Not declared in ClinicalTrials.gov 5 9.8 7 12.1
Secondary Outcomea
Corresponded 16 43.2 34 64.2
Not corresponded 12 32.4 11 20.8
Not declared in ClinicalTrials.gov 9 24.3 8 15.1
aSome discrepancies in the total are due to missing data
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This analysis has some limitations. Misclassification of
clinical trials might have influenced the data collection,
as well as the lack of updating by investigators. In
addition, the analysis was restricted to the period be-
tween 2008 and 2015 and some journal articles might
have been missed, considering the time needed for peer
review before publication. As concern strengths, this
paper adds evidence to the discussion about the lack of
transparency of clinical research, showing that the prob-
lem is far from solved.
Conclusions
Researchers, clinicians and citizens or patients’ representa-
tives need to focus on transparency as an important eth-
ical issue and continuously support initiatives to improve
the publication and dissemination of clinical findings. The
publication of protocols and statistical analysis plans could
be useful to ensure transparency through the investigators
themselves should be more compliant or explain discrep-
ancies [36]. In addition, publishers and editors should pay
close attention to ensure that information reported in
ClinicalTrials.gov is consistent with the information re-
ported in papers submitted.
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